Morning Market Losers

shares fell 25.08% to $2.45 after the company reported Phase 2a study results for ASONEP in renal cell carcinoma.

shares tumbled 18.69% to $22.76 after the company reported narrower-than-expected loss for its fiscal second quarter, but issued a weak sales forecast.

shares slipped 12.65% to $5.12 after the company posted fourth-quarter results and issued a weak revenue outlook.

shares declined 9.88% to $24.26 after the company announced that a unit of its

affiliate will launch a public offering of 22.8 million units.

fell 9.39% to $28.22 after the company announced the pricing of 17.5 million common stock.

shares declined 6.51% to $1.15 after the company named CEO Michael Bodouroglou as Interim CFO.

dropped 5.80% to $4.55 after the company reported downbeat Q4 results and issued a weak outlook.

shares dipped 4.11% to $8.87 after the company announced a $175 million offering of shares.

shares slipped 3.97% to $1.45 after the company reported that it has raised $25 million in private placement of convertible preferred stock.